Cardiac sarcoidosis: what to do when first-line corticosteroid treatment has not controlled myocardial inflammation
This protocol covers patients with cardiac sarcoidosis in whom initial corticosteroid therapy has not produced adequate suppression of active myocardial inflammation, or who have not had sufficient resolution of associated conduction disturbances or heart failure. A more intensive combination strategy is indicated.
Previous treatment — inadequate response
First-line corticosteroid therapy did not achieve the expected targets: cardiac FDG-PET at 2–6 months did not show decreased or resolved myocardial inflammation, and/or arrhythmias, heart block, or heart failure did not improve or resolve. Escalation to a next-line regimen is warranted.
Next-line approach (partial overview)
The next step introduces a previously unused steroid-sparing agent added to an adjusted corticosteroid regimen — a combination strategy aimed at suppressing persistent myocardial granulomatous inflammation. The complete regimen, agent selection, and dose-titration guidance are in the structured protocol.
Treatment target
Response is assessed at 2 to 6 months. The goal is cardiac FDG-PET showing minimal residual or resolved myocardial inflammation, alongside clinical improvement in arrhythmias, conduction abnormalities, or heart failure where present.
References
DOI: 10.1161/CIR.0000000000001240
- In a tiered approach to treatment, individuals with relapse or ongoing inflammation after corticosteroids would receive a second-line agent (methotrexate, mycophenolate, azathioprine, or leflunomide) in combination with corticosteroids.
- The response to treatment is measured in 2 ways: (1) improvement or resolution of the clinical presentation of arrhythmias, heart block, or HF and (2) reduction in the degree of active granulomatous inflammation in the myocardium.
View source ↗